Immune to Cancer: The CRI Blog
-
FDA Approves Pembrolizumab Immunotherapy for Advanced Liver Cancer
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1…
-
Voices Amongst the Crowd at 2018 TCS New York City Marathon
Sixteen Team CRI runners ran the 26.2 mile 2018 TCS New York City Marathon and raised an…
-
Fundraising and Fighting Cancer with Music for a Cause
On September 28, 2018, Conversing with Oceans organized a concert and fundraiser in the Bronx to support…
-
CRI Celebrates its 65th Birthday
On Thursday, October 25, the Cancer Research Institute held its annual awards gala to celebrate its 65th…
-
CICON18 Day 4 Update: The Role of Bacteria; Technologies to Advance Cancer Immunotherapy
The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the…
-
CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…
-
Dr. James P. Allison, CRI Scientific Director, Awarded 2018 Nobel Prize along with Dr. Tasuku Honjo
Dr. Allison’s discoveries and determination led to the development of the first FDA-approved checkpoint immunotherapy
-
Cemiplimab Becomes First Treatment Approved for Advanced Cutaneous Squamous Cell Carcinoma
Immunotherapy is now approved for patients with advanced forms of the second most common form of skin…
-
CICON18 Preview: Translating Science into Survival
Highlights from the upcoming International Cancer Immunotherapy Conference (CICON18), including regulating T cell response, tackling the tumor…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.